Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

On May 23, 2011, the Food and Drug Administration approved telaprevir (Incivek®), an hepatitis C virus (HCV) protease inhibitor. Telaprevir is the second direct acting antiviral drug against the hepatitis C virus to be approved.

FDA Notifications: HCV virus protease inhibitor is approved